Compare VHC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | MIRA |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 37.1M |
| IPO Year | 2008 | 2023 |
| Metric | VHC | MIRA |
|---|---|---|
| Price | $13.26 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.6K | ★ 87.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3140.00 | N/A |
| 52 Week Low | $9.82 | $0.60 |
| 52 Week High | $29.00 | $2.45 |
| Indicator | VHC | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.39 |
| Support Level | N/A | $0.60 |
| Resistance Level | N/A | $0.83 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 49.23 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. Its software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.